Ghostwriting in medical literature

International Journal of Occupational and Environmental Health

Volumn 17, Issue 2, 2011, Pages 168-177

  Grassley, Charles E ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DRUG INDUSTRY; ETHICS; HUMAN; INTERPERSONAL COMMUNICATION; MEDICAL RESEARCH; MEDICAL SCHOOL; PUBLICATION; PUBLISHING; WRITING;

AUTHORSHIP; BIOMEDICAL RESEARCH; DISCLOSURE; DRUG INDUSTRY; EDITORIAL POLICIES; HUMANS; PERIODICALS AS TOPIC; SCHOOLS, MEDICAL;

EID: 79955105280     PISSN: 10773525     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Committee Staff Report to the Chairman and Ranking Member, Use of Educational Grants by Pharmaceutical Manufacturers, S. Prt. 110-21, April 2007, available from: http://finance.senate.gov/newsroom/chairman/release/?id=af4af834-3fab-4293-be6d-ca7f1246484f
2. Pub. L. No. 111-148, § 6002 (2010).
3. Merck removed Vioxx from the market in 2004 because of cardiovascular risks.
4. Ross JS, Hill KP, et al. "Guest Authorship and Ghostwriting in Publications Related to Rofecoxib, " JAMA, 2008;299(15): 1800-1812.
5. Pfizer, Inc. acquired Wyeth on October 15, 2009.
6. DesignWrite email, March 24, 1999, is included as Attachment 1 in the full report. Available at: http://grassley.senate.gov/about/upload/Senator-Grassley-Report.pdf.
7. Eden J. "Progestins and Breast Cancer, " Am J Obstet Gynecol, 2003;188(5):1123-1131.
8. Nachtigall LE. "Sex Hormone-Binding Globulin and Breast Cancer Risk, " Prim Care Update OB/GYNs, 1999;6(3):39-45.
9. Bush TL, Whiteman M, and Flaws JA. "Hormone Replacement Therapy and Breast Cancer: A Qualitative Review, " Obstet Gynecol, 2001;98(3):498-508.
10. Lacasse J, Leo J. "Ghostwriting at Elite Academic Medical Centers in the United States, " PLoS Med, 2010;7(2):1-4.
11. DesignWrite email from Medical Writer to physician, November 17, 1999, is included as Attachment 2 in the full report. Available from: http://grassley.senate.gov/about/upload/Senator-Grassley-Report.pdf.
12. Scientific Therapeutics Information, Vioxx Secondary Publication Program Scientific Communications Plan, submitted to Merck & Co., Jun. 3, 1999. Included as Attachment 3 in the full report. Available from: http://grassley.senate.gov/about/upload/Senator-Grassley-Report.pdf.
13. Declaration of Virginia Barbour in support of the Public Library of Science's Motion to Intervene and Motion for Access to Discovery Materials, In re Prempro Products Liability Litigation (D. Ark. 2009), available from: http://www.plosmedicine.org/static/ghostwritingDeclaration.pdf.
14. Garnett WR, "Clinical Implications of Drug Interactions with Coxibs, " Pharmacotherapy, 2001;21(10):1223-1232.
15. "Policy on External Publications and Presentation, " Wyeth Pharmaceutical Policies, Policy 513, May 4, 2006.
16. Pfizer's policy on public disclosure and authorship of Pfizersponsored clinical trials is available from: http://www.pfizer.com/research/research_clinical_trials/registration_disclosure_authorship.jsp
17. International Committee of Medical Journal Editors, Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Ethical Considerations in the Conduct and Reporting of Research: Authorship and Contributorship. Available from: http://www.icmje.org/ethical_1author.html.
18. Columbia, Duke, Harvard, Johns Hopkins Medicine, UW Medicine, Washington, and Yale.
19. Email to STI, August 14, 2000, is included as Attachment 4 in the full report. Available at: http://grassley.senate.gov/about/upload/Senator-Grassley-Report.pdf.
20. AMA Manual of Style: A Guide for Authors and Editors (10th ed.), available from: http://www.amamanualofstyle.com.
21. American Medical Association, Authorship Responsibility, Financial Disclosure, Acknowledgment, and Copyright Transfer/ Publishing Agreement, reprinted from Arch Intern Med/Vol 170 (9), May 10, 2010. Included as Attachment 5 in the full report. Available at: http://grassley.senate.gov/about/upload/Senator-Grassley-Report.pdf.
22. Jacobs A, Wager E. "European Medical Writers Association (EMWA) guidelines on the role of medical writers in peerreviewed publications, " Curr Med Res Opin, 2005;21(2): 317-321.
23. Wislar J, Flanagin A, et al. "Prevalence of Honorary and Ghost Authorship in 6 General Medical Journals, 2009, " Paper presented at the Sixth International Congress on Peer Review and Biomedical Publication, Vancouver, British Columbia, Canada, Sept. 10, 2009.
24. Flanagin A, Carey LA, et al. "Prevalence of Articles with Honorary Authors and Ghost Authors in Peer-Reviewed Medical Journals", JAMA, 1998; 280(3): 222-224.
25. Gever J. "Fewer Medical Journal Articles Planted by Phantom Authors, " MedPage Today, April 14, 2008.
26. Available on the Drug Industry Document Archive at http://dida.library.ucsf.edu/pdf/atb37b10.
27. Institute of Medicine, Conflict of Interest in Medical Research, Education, and Practice (2009).
28. Bero L, and White J. "Ghost Writing: How Some Journals Aided and Abetted the Marketing of a Drug", Paper presented at the Sixth International Congress on Peer Review and Biomedical Publication, Vancouver, British Columbia, Canada, Sept. 10, 2009.
29. See http://finance.senate.gov/newsroom/ranking/release/?id=67b016e1-58dd-4f7f-acaa-05fce22393a1; see also http://finance.senate.gov/newsroom/ranking/release/?id=91aa840ce86d-476d-a8fa-300220d602e0.
30. Gotzche PC, Kassirer JP, Woolley KL et al. "What Should Be Done to Tackle Ghostwriting in the Medical Literature?" PLoS Med, 2009;6(2):122-125.
31. American Family Physician, Full Disclosure for CME Activities, Jun. 2006, is included as Attachment 6 in the full report. Available at: http://grassley.senate.gov/about/upload/Senator-Grassley-Report.pdf.